Conference

Big new insights on diabetes treatments and technology emerged from the American Diabetes Association’s (ADA) 2026 conference in New Orleans. Here’s what matters most for people living with diabetes.

Afrezza, an ultra rapid-acting inhaled insulin, offers an alternative to injections for mealtime glucose management. It starts working in 12 minutes and works well for some, but not for all people with diabetes. 

Big new insights on diabetes treatments, technology, and risks emerged from the 2026 Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona. Here’s what matters most for people living with diabetes.

Learn about the automated insulin delivery system's features, how it works, what it costs — and get the latest news.

Curious to see how much you know about diabetes? Learn in an exciting new way as experts in the field go head-to-head for the first time in Diabetes Jeopardy!, hosted by TCOYD and diaTribe.

Data from Bayer’s FINEARTS-HF trial showed finerenone (Kerendia) reduced the onset of type 2 diabetes, heart failure, and cardiovascular death in people with heart failure.